Over the years, I’ve had the good fortune to work as a trial lawyer on some very interesting issues in cases at intersections between...

Some day I would love to find a law review or treatise capturing and summarizing the various industries which hold legislative immunity...

Interesting June 25, 2018 interview/article in Corporate Counsel on the expansion of the ILR through acquisition of news media, and its...

Sponsored research is needed to answer some questions. This seems especially true in an age in which government budgets are less than...

The Springer v.  Nohl fraudulent conveyance/asbestos case in Wisconsin highlights dubious corporate side activities, and  is finally...

It seems to be a week for articles highlighting the more tawdry side of the plaintiff side in mass torts. In this instance, a new Forbes...

For an outlier  example of some of the worst of mass tort claiming, proceed directly to Mass Torts and Mass Fraud, the June 6, 2018 post...

A $1 billion compensatory damages verdict last week seems to be another signal of significant unhappiness among the people who are...

Yesterday’s punitive damages verdict against J&J arrived after interesting questions from the jury to the court. One wonders how J&J will...

Part of the seamy side of vaginal mesh litigation was reported in an April 14, 2018 article in the NYT. The article, “How Profiteers Lure...

Once upon a time, it seemed the 1980 ruling in  World-Wide Volkswagen would control forever, and that jurisdictional jurisdictional...

Some circuit courts had issued fairly hard to fathom opinions immunizing some corporate  transactions from fraudulent conveyance claims...

Biomarkers are changing many aspects of science and litigation. The field is still young, but promising. The point is exemplified by...

An upcoming workshop looks interesting as to class action and “tort reform” topics. The agenda is online here, and pasted below.  A hat...

After an alleged or actual mass tort, some companies move voluntarily into chapter 11 proceedings to cope with the claims. However, some...

ToxicoGenomica is the doing business name for a collaboration between me and scientists at ArrayXpress and Innovative Science Solutions....

Advances in gene therapy are accelerating the pace and scale of the revolution in molecular biology. A new, open access review article in...

Yet another example of how biomarkers evolve, and could matter for litigation over alleged or actual injuries, as set out in a September...

Talc litigation is providing yet another example of the reality that product liability litigation can be complicated by multiple parties...

How to think about the future, and the past? Some proclaim “certainty” essential and demand “proof” with confidence intervals at .05% or...